USP7 accelerates FMR1-mediated ferroptosis by facilitating TBK1 ubiquitination and DNMT1 deubiquitination after renal ischemia-reperfusion injury
Composition Epitalon: 50 mg Appearance: lyophilized powder in a sealed research vial Research Focus (non-clinical) Peptide identity and purity assessment Assay development and calibration for quantitative analysis Chromatographic method optimization for impurity profiling and peak resolution Stability characterization of a lyophilized peptide under laboratory storage conditions Documentation Lot-specific COA available Batch and lot traceability Important Notice For research use only Not for human consumption Not intended to diagnose, treat, cure, or prevent any disease Quality & Manufacturing Lot-specific COA Lyophilized for transit stability
This calculator helps translate between: IU and millilitres (mL) millilitres and syringe units This is particularly useful when interpreting prescriptions or switching between dilution volumes
The peptide accelerates wound closure (96% closure by day 11 in enhanced formulations), stimulates blood vessel formation (angiogenesis), promotes nerve outgrowth, reduces scar formation through organized collagen deposition, and attracts immune cells for tissue remodeling
For research only, Do not use for Human
ABMR cells exhibited lower OXPHOS, citrate (TCA cycle), glutathione metabolism, and vitamin A and biosynthetic machinery (valine, leucine, and isoleucine degradation